.Pharmacolibrary.Drugs.ATC.J.J05AX29 .Pharmacolibrary.Drugs.ATC.J.J05AX29| name: | Fostemsavir |
| ATC code: | J05AX29 | route: | oral |
| n-compartments | 2 |
Fostemsavir is an antiretroviral medication used for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom an otherwise suppressive antiretroviral regimen is not available. It is a prodrug of temsavir, which acts as an attachment inhibitor binding to gp120 on HIV-1, preventing virus attachment and entry into host CD4+ cells. Fostemsavir is FDA- and EMA-approved.
Population pharmacokinetics of temsavir (the active moiety of fostemsavir) in HIV-1-infected adults, following oral administration of fostemsavir 600 mg twice daily.
Magee, M, et al., & Moore, K (2021). Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir. Journal of clinical pharmacology 61(7) 939–953. DOI:10.1002/jcph.1810 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33368327
Beran, C, et al., & Sahloff, EG (2024). A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 40(4) 194–201. DOI:10.1177/87551225241259894 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39157636
Landry, I, et al., & Bertz, RJ (2016). Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529. Antimicrobial agents and chemotherapy 60(5) 2782–2789. DOI:10.1128/AAC.02503-15 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26902761